Evaluating the effect of Glycyrrhiza glabra, Matricaria chamomilla, and Achillea millefolium on the symptoms of irritable bowel syndrome: Clinical trial
Effect of three plants on IBS
DOI:
https://doi.org/10.22122/cdj.v11i4.671Keywords:
Glycyrrhiza Glabra, Matricaria Chamomilla, Achillea Millefolium, Irritable bowel syndromeAbstract
BACKGROUND: Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal (GI) tract that causes multiple and occasionally debilitating symptoms in patients. Given the high prevalence and wide effects of IBS in our society, finding cheap, safe, and effective drugs has a great importance for helping the patients with IBS and helping the community's health economy. The aim of this study was to determine the effect of yarrow, licorice, and chamomile (as a cheap and safe cocktail) on the symptoms of patients with IBS.
METHODS: In this double-blinded clinical trial study, 102 patients (referred to Toohid Hospital in Sanandaj City, Kurdistan, Iran, from February 25, 2017 to August 21, 2019) were included in the trial. The diagnosis of IBS was based on clinical findings and Rome-III criteria. Subjects were randomly assigned to intervention and control groups. The intervention group was given a combination of three plants [Glycyrrhiza glabra (G. glabra), Matricaria chamomilla (M. chamomilla), and Achillea millefolium (A. millefolium)] for a month. The control group received a placebo. Outcomes were assessed 2 and 4 weeks later. Data were analyzed using SPSS software.
RESULTS: The mean age of the subjects was 41.2 ± 11.6 years (age range: 21-60 years). 42 patients (41.17%) were men, and 60 patients (58.8%) were women. The mean duration of the symptoms was 27.4 [standard deviation (SD) = 24.6] months. Two weeks after the intervention, there was a statistically significant difference between the two groups in terms of some symptoms, including constipation, diarrhea, and mucus excretion. Four weeks after the intervention, there was a statistically significant difference between the two groups in terms of abdominal pain, bloating, constipation, diarrhea, and feeling of incomplete excretion (P = 0.001).
CONCLUSION: Based on the results of this study, combination of the three plants (G. glabra, M. chamomilla, and A. millefolium) was effective in reducing the symptoms of IBS.
References
Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review. JAMA. 2015; 313(9): 949-58.
Hillila MT, Farkkila NJ, Farkkila MA. Societal costs for irritable bowel syndrome--a population based study. Scand J Gastroenterol. 2010; 45(5): 582-91.
Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic G, Zivkovic V. Irritable bowel syndrome - from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018; 162(1): 1-9.
Baysoy G, Guler-Baysoy N, Kesicioglu A, Akin D, Dundar T, Pamukcu-Uyan A. Prevalence of irritable bowel syndrome in adolescents in Turkey: Effects of gender, lifestyle and psychological factors. Turk J Pediatr. 2014; 56(6): 604-11.
Gwee KA, Ghoshal UC, Chen M. Irritable bowel syndrome in Asia: Pathogenesis, natural history, epidemiology, and management. J Gastroenterol Hepatol. 2018; 33(1): 99-110.
Jahangiri P, Jazi MS, Keshteli AH, Sadeghpour S, Amini E, Adibi P. Irritable bowel syndrome in Iran: SEPAHAN Systematic Review No. 1. Int J Prev Med. 2012; 3(Suppl 1): S1-S9.
Camara-Lemarroy CR, Escobedo-Zuniga N, Ortiz-Zacarias D, Pena-Avendano J, Villarreal-Garza E, Diaz-Torres MA. Prevalence and impact of irritable bowel syndrome in people with epilepsy. Epilepsy Behav. 2016; 63: 29-33.
Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017; 66(6): 1075-82.
Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil. 2012; 18(3): 258-68.
Waller DG, Sampson A, Hitchings A. Medical pharmacology and therapeutics: medical pharmacology and therapeutics, E-Book. Elsevier Health Sciences; 2021.
Goldman L, Schafer AI. Goldman's Cecil Medicine. Philadelphia, PA: Elsevier, Saunders; 2011.
El-Serag H, Hill C, Jones R. Systematic review: The epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther. 2009; 29(5): 470-80.
Tobin MC, Moparty B, Farhadi A, DeMeo MT, Bansal PJ, Keshavarzian A. Atopic irritable bowel syndrome: A novel subgroup of irritable bowel syndrome with allergic manifestations. Ann Allergy Asthma Immunol. 2008; 100(1): 49-53.
Powell N, Huntley B, Beech T, Knight W, Knight H, Corrigan CJ. Increased prevalence of gastrointestinal symptoms in patients with allergic disease. Postgrad Med J. 2007; 83(977): 182-6.
Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry. 2009; 70 Suppl 2: 20-4.
Panicker R, Arifhodzic N, Al Ahmad M, Ali SA. Association and symptom characteristics of irritable bowel syndrome among bronchial asthma patients in Kuwait. Ann Thorac Med. 2010; 5(1): 37-42.
Jenabi E, Fereidoony B. Effect of Achillea millefolium on relief of primary dysmenorrhea: A double-blind randomized clinical trial. J Pediatr Adolesc Gynecol. 2015; 28(5): 402-4.
Zakeri S, Esmaeilzadeh S, Gorji N, Memariani Z, Moeini R, Bijani A. The effect of Achillea millefolium L. on vulvovaginal candidiasis compared with clotrimazole: A randomized controlled trial. Complement Ther Med. 2020; 52: 102483.
Ayoobi F, Moghadam-Ahmadi A, Amiri H, Vakilian A, Heidari M, Farahmand H, et al. Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial. Phytomedicine. 2019; 52: 89-97.
Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(10): 908-17.
Rahimian G, Babaeian M, Kheiri S, Moradi MT, Rafieian-Kopaei M. Effect of Glycyrrhiza glabra (D-reglis tablet) on pain and defecation of patients with irritable bowel syndrome. J Birjand Univ Med Sci. 2010; 17(4): 240-8.
Agah S, Taleb AM, Moeini R, Gorji N, Nikbakht H, Soltani M. Chamomile efficacy in patients of the irritable bowel syndrome. Der Pharma Chemica. 2015; 7: 41-5.
Raveendra KR, Jayachandra, Srinivasa V, Sushma KR, Allan JJ, Goudar KS, et al. An Extract of Glycyrrhiza glabra (GutGard) alleviates symptoms of functional dyspepsia: A randomized, double-blind, placebo-controlled study. Evid Based Complement Alternat Med. 2012; 2012: 216970.
Anheyer D, Frawley J, Koch AK, Lauche R, Langhorst J, Dobos G, et al. Herbal medicines for gastrointestinal disorders in children and adolescents: A systematic review. Pediatrics. 2017; 139(6).
Kazemian A, Toghiani A, Shafiei K, Afshar H, Rafiei R, Memari M, et al. Evaluating the efficacy of mixture of Boswellia carterii, Zingiber officinale, and Achillea millefolium on severity of symptoms, anxiety, and depression in irritable bowel syndrome patients. J Res Med Sci. 2017; 22: 120.
Biondi DM, Rocco C, Ruberto G. New dihydrostilbene derivatives from the leaves of Glycyrrhiza glabra and evaluation of their antioxidant activity. J Nat Prod. 2003; 66(4): 477-80.
Sato Y, He JX, Nagai H, Tani T, Akao T. Isoliquiritigenin, one of the antispasmodic principles of Glycyrrhiza ularensis roots, acts in the lower part of intestine. Biol Pharm Bull. 2007; 30(1): 145-9.
Derakhshande P, Navabi SJ, Shokoohinia Y, Rouhi-Broujeni H, Deris F, Behbood L, et al. Efficacy and safety of Achillea wilhelmsii C. Koch capsules on symptom severity and quality of life in patients with irritable bowel syndrome: A randomized, placebo-controlled clinical trial. J Complement Integr Med. 2019; 16(4): doi: 10.1515/jcim-2018-0123.
Gharib Naseri MK, Arabian M, Gharib Naseri Z. Antispasmodic effect of hydroalcoholic leaf extract of licorice ileum contraction in rat. J Shahrekord Univ Med Sci. 2008; 9(3): 1-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Chronic Diseases Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
